OTCMKTS:EPGNY Epigenomics - EPGNY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Epigenomics AG Please log in to your account or sign up in order to add this asset to your watchlist. $2.39 0.00 (0.00%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.39▼$2.3950-Day Range$2.39▼$9.5652-Week Range$2.01▼$2.39VolumeN/AAverage Volume100 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlinesShort Interest About Epigenomics (OTCMKTS:EPGNY) StockEpigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.Read More Receive EPGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Epigenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address EPGNY Stock News HeadlinesMarch 20, 2023 | uk.finance.yahoo.comEpigenomics AG: Adjustment of guidance and notice of loss pursuant to sec. 92 para. 1 of the German Stock Corporation ActMarch 14, 2023 | benzinga.comSample Preparation in Genomics, Proteomics, and Epigenomics Global Market Report 2023: Increased R&D Spending in Developing Economies Boosts SectorMarch 22, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.March 10, 2023 | uk.finance.yahoo.comEpigenomics AG: Revocation of admission to the Prime Standard (sub-segment of the regulated market with additional post-admission obligations)February 21, 2023 | marketwatch.comPersonalized Medicine and Epigenomics Market Capitalizing on Market Growth: Essential Insights from Our Latest Research ReportJanuary 27, 2023 | uk.finance.yahoo.comEpigenomics AG: Resignation of Supervisory Board Chairman Heino von ProndzynskiJanuary 27, 2023 | markets.businessinsider.comEQS-News: Epigenomics AG: Resignation of Supervisory Board Chairman Heino von ProndzynskiDecember 23, 2022 | markets.businessinsider.comEQS-News: Pareto Securities AS publishes buy recommendation for Epigenomics AG shareMarch 22, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.December 21, 2022 | markets.businessinsider.comEQS-Adhoc: Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022December 14, 2022 | markets.businessinsider.comEQS-Adhoc: Epigenomics Releases Performance Data on Next Generation TestDecember 14, 2022 | uk.finance.yahoo.comEpigenomics Releases Performance Data on Next Generation TestDecember 14, 2022 | markets.businessinsider.comEQS-News: Epigenomics Releases Performance Data on Next Generation TestDecember 14, 2022 | markets.businessinsider.comEQS-News: Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer TestSeptember 19, 2022 | markets.businessinsider.comEQS-Adhoc: Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costsSeptember 19, 2022 | uk.finance.yahoo.comEpigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer testSeptember 19, 2022 | markets.businessinsider.comEQS-News: Epigenomics Initiates prospective multi-center clinical trial for Next-Generation blood-based colorectal cancer testSeptember 9, 2022 | markets.businessinsider.comDGAP-Adhoc: Epigenomics AG: Capital reduction planned at a ratio of 4 : 1August 15, 2022 | uk.finance.yahoo.comEpigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktGAugust 15, 2022 | markets.businessinsider.comDGAP-News: Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktGAugust 10, 2022 | markets.businessinsider.comDGAP-News: Epigenomics AG Reports Financial Results for the First Six Months of 2022May 11, 2022 | uk.finance.yahoo.comEpigenomics AG Reports Financial Results for the First Quarter of 2022May 11, 2022 | markets.businessinsider.comDGAP-News: Epigenomics AG Reports Financial Results for the First Quarter of 2022March 30, 2022 | marketwatch.comGlobal Personalized Medicine and Epigenomics Market 2022 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2028March 24, 2022 | markets.businessinsider.comDGAP-News: Epigenomics AG Reports Financial Results for Fiscal Year 2021January 14, 2022 | nasdaq.comEPGNY After-Hours QuotesJanuary 6, 2022 | nasdaq.comEPGNY Real-Time QuotesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EPGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Epigenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:EPGNY CUSIPN/A CIKN/A Webwww.epigenomics.com Phone(493) 024-3450FaxN/AEmployees32Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesMr. Gregory K. Hamilton (Age 52)CEO & Member of the Exec. Board Comp: $828.44kDr. Andrew A. Lukowiak Ph.D. (Age 50)Pres & Chief Scientific Officer Comp: $387.44kMr. Jens Ravens (Age 52)CFO & Member of Exec. Board Frederic HilkeInvestor Relations OfficerDr. Noel Thomas DohenyChief Exec. Officer of Epigenomics Inc.Key CompetitorsbioAffinity TechnologiesNASDAQ:BIAFWEternity HealthcareOTCMKTS:ETAHImagin MedicalOTCMKTS:IMEXFMany Bright Ideas TechnologiesOTCMKTS:MBGNFMedical ImagingOTCMKTS:MEDDView All Competitors EPGNY Stock - Frequently Asked Questions How have EPGNY shares performed in 2023? Epigenomics' stock was trading at $9.56 at the beginning of 2023. Since then, EPGNY stock has decreased by 75.0% and is now trading at $2.39. View the best growth stocks for 2023 here. What is Epigenomics' stock symbol? Epigenomics trades on the OTCMKTS under the ticker symbol "EPGNY." How do I buy shares of Epigenomics? Shares of EPGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Epigenomics' stock price today? One share of EPGNY stock can currently be purchased for approximately $2.39. How can I contact Epigenomics? Epigenomics' mailing address is Geneststrasse 5, Berlin, Berlin 10829. The official website for the company is www.epigenomics.com. The company can be reached via phone at (493) 024-3450. This page (OTCMKTS:EPGNY) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.